Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 17/20 | 0.57 |
| ▸ | TACR3 | P29371 | 16/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.56 |
| ▸ | TRPV4 | Q9HBA0 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5450761 | 0.92 | TACR2 (0.68) | TACR2TACR3OPRM1TRPV4 | |
| SCHEMBL5438071 | 0.91 | TACR2 (0.60) | TACR2TACR3OPRM1TRPV4 | |
| SCHEMBL6200585 | 0.90 | TACR2 (0.47) | TACR2TACR3OPRM1TRPV4 | |
| SCHEMBL5450756 | 0.88 | TACR2 (0.69) | TACR2TACR3OPRM1TRPV4 | |
| SCHEMBL5442112 | 0.86 | DHODH (0.52) | — | |
| SCHEMBL5937385 | 0.86 | TACR2 (0.56) | TACR2TACR3OPRM1TRPV4 | |
| SCHEMBL5937443 | 0.84 | TACR2 (0.54) | TACR2TACR3OPRM1TRPV4 | |
| SCHEMBL5442075 | 0.83 | TACR2 (0.69) | TACR2TACR3OPRM1TRPV4 | |
| SCHEMBL5908809 | 0.83 | TACR2 (0.69) | TACR2TACR3OPRM1TRPV4 | |
| SCHEMBL6268952 | 0.83 | TACR3 (0.54) | TACR2TACR3OPRM1TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161647-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 and NK-2 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE S.P.A. | 2007-07-12 | — | — | US | disclosed |
| US-20050176762-A1 | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | GLAXOSMITHKLINE SPA | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161647-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 and NK-2 RECEPTOR ANTAGONISTS | KCNQ3, KCNK3, KCNK2 | TACR2 22/4885TACR3 45/4885OPRM1 733/4885 |
| US-20050176762-A1 | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | KCNQ3, KCNK3, KCNK2 | TACR2 22/4885TACR3 45/4885OPRM1 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.